When was Milestone Pharmaceuticals founded?

Milestone Pharmaceuticals was founded in 2005 and raised its 1st funding round 2 years after it was founded.

Where is Milestone Pharmaceuticals located?

Milestone Pharmaceuticals is headquartered in Montreal, Canada.

How many employees does Milestone Pharmaceuticals have?

As of Aug 31, 2026, the latest employee count at Milestone Pharmaceuticals is 130.

Is Milestone Pharmaceuticals a funded company?

Milestone Pharmaceuticals is a funded company, having raised a total of $174M across 9 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Aug 07, 2007.

When was the latest funding round of Milestone Pharmaceuticals?

Milestone Pharmaceuticals' latest funding was a $***** Post IPO round on Mar 28, 2023, with participation from 1 investor.

What is the annual revenue of Milestone Pharmaceuticals?

Annual revenue of Milestone Pharmaceuticals is between $1M and $10M as on Dec 31, 2022

Where does Milestone Pharmaceuticals rank among its competitors?

Milestone Pharmaceuticals ranks 31st amongst 370 active competitors, of which 112 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Rejuvenate Bio, which secured $19.5M in Jun, 2026.

Who are the top competitors of Milestone Pharmaceuticals?

Milestone Pharmaceuticals' top competitors include argenx, Tenaya Therapeutics and Vor Biopharma. Among them, Rejuvenate Bio secured the most recent funding round in June, 2026.

Milestone Pharmaceuticals - 2026 Company Profile, Funding, Competitors & Financials

Milestone Pharmaceuticals is a public company based in Montreal (Canada), founded in 2005. It operates as a Provider of small molecule based drug development for treating cardio vascular conditions. Milestone Pharmaceuticals has raised $174M in funding from investors like Inovia Capital, BDC and Fonds de solidarite FTQ. The company has 370 active competitors, including 112 funded and 105 that have exited. Its top competitors include companies like argenx, Tenaya Therapeutics and Vor Biopharma.

Company Details

Provider of small molecule based drug development for treating cardio vascular conditions. The company's lead product is a novel and potent short-acting calcium channel antagonist for the systemic treatment of transient cardiovascular conditions such as atrial arrhythmias and angina. The product is being developed as a nasal spray to provide for rapid systemic drug delivery.

Key Metrics

Founded Year

2005

Location

Montreal, Canada

Stage

Public

Total Funding

$174M in 9 rounds

Latest Funding Round

Post IPO, Mar 28, 2023, $*****

Investors

Inovia Capital & 16 more

Ranked

31^st among 370 active competitors

Annual Revenue

$1M - $10M as on Dec 31, 2022

Employee Count

130 as on Aug 31, 2026

Similar Companies

Tenaya Therapeutics & 349 more

Exit Details

Public

View Milestone Pharmaceuticals' full profile

Milestone Pharmaceuticals is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Milestone Pharmaceuticals Inc. CIN: 1408443 , United States, Active	Jan 24, 2017	$1M - $10M (As on Dec 31, 2022)	-	-
MILESTONE PHARMACEUTICALS USA INC. CIN: 815198483 , United States, Active	Dec 31, 1999	-	23 (As on Dec 31, 2024)	-

Milestone Pharmaceuticals got listed on May 09, 2019.

Click here to take a look at Milestone Pharmaceuticals's IPO in detail

Milestone Pharmaceuticals has raised a total funding of $174M over 9 rounds. Its first funding round was on Aug 07, 2007. Its latest funding round was a Post IPO round on Mar 28, 2023 for $*****. 1 investor participated in its latest round. Milestone Pharmaceuticals has 17 institutional investors.

Here is the list of recent funding rounds of Milestone Pharmaceuticals:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 28, 2023	2406448	Post IPO	7080390	4180284	6671821	6524319
Jul 23, 2020	6778036	Post IPO	2444895	7700674	3612355	RTW Investments
Oct 15, 2018	1520988	Series D	6043391	7816849	RTW Investments	Novo Holdings & 9 more

Access funding benchmarks and valuations. Sign up today!

View details of Milestone Pharmaceuticals's funding rounds and investors

Milestone Pharmaceuticals' employee count trend

Milestone Pharmaceuticals has 130 employees as of Aug 26. Here is Milestone Pharmaceuticals's employee count trend over the years:

Employee count trend for Milestone Pharmaceuticals

Uncover Milestone Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Milestone Pharmaceuticals include argenx, Tenaya Therapeutics and Vor Biopharma. Here is the list of Top 10 competitors of Milestone Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
2nd	Tenaya Therapeutics 2016, San Francisco (United States), Public	Developer of regenerative and gene therapeutics for heart failure	$248M	RTW Investments, Fidelity Investments & 7 others	70/100
3rd	Vor Biopharma 2019, Cambridge (United States), Public	Developer of therapeutics to treat acute myeloid leukemia	$152M	NEXTBio, Mingxin Capital & 10 others	68/100
4th	Kiniksa Pharmaceuticals 2015, Lexington (United States), Public	Developer of therapeutics for multiple diseases treatment	$320M	Fidelity Investments, Sofinnova Investments ... & 8 others	66/100
5th	Ventyx Biosciences 2018, Encinitas (United States), Acquired	Developer of therapeutics to treat autoimmune diseases	$165M	VenBio, Logos Capital & 13 others	66/100
6th	Esperion Therapeutics 1998, Ann Arbor (United States), Acquired	Developer of lipoprotein cholesterol (LDL-C) lowering therapies	$107M	Alta Partners, Longitude Capital & 16 others	66/100
7th	Structure 2017, San Francisco (United States), Public	Developer of oral small molecule drugs for chronic diseases	$191M	BVF Partners, Janus Henderson Investors & 17 others	65/100
8th	Cellino 2017, Cambridge (United States), Series A	Developer of autologous cell therapies	$125M	Humboldt Fund, Leaps by Bayer & 7 others	65/100
9th	Radius Health 2003, Boston (United States), Acquired	Biopharmaceutical company focused on bone health and related therapeutic areas	$213M	MPM BioImpact, Wellcome & 14 others	63/100
10th	Rejuvenate Bio 2018, San Diego (United States), Series A	Developer of gene therapies for treating chronic and age-related diseases	$34M	VCapital, Digitalis Ventures & 12 others	62/100
31st	Milestone Pharmaceuticals 2005, Montreal (Canada), Public	Provider of small molecule based drug development for treating cardio vascular conditions	$174M	RTW Investments, Boxer Capital & 15 others	56/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Milestone Pharmaceuticals's competitors? Click here to see the top ones

Milestone Pharmaceuticals has made no investments or acquisitions yet.

Here is the latest report on Milestone Pharmaceuticals's sector:

Free

Cardiac and Vascular Disorders - Sector Report

Edition: August, 2026 (67 Pages)

View all reports related to Milestone Pharmaceuticals

Media has covered Milestone Pharmaceuticals for a total of 13 events in the last 1 year, 8 of them have been about company updates and 1 about people movement.